←Back to list

Rightway

Transparent pharmacy benefit manager (PBM) with clinician-led care navigation for employers
Rightway is a New York-based pharmacy benefit manager and care navigation company that sells employers a transparent PBM model: a per-enrollee fee untethered to drug prices, 100% rebate pass-through and a total pharmacy spend guarantee (SureSpend), with pharmacists guiding members to high-value medications. It counts 45 Fortune 500 companies as clients, serves about 3 million people and says it is profitable; Eli Lilly moved its employee plan to Rightway and Mayo Clinic is slated to switch in January. On 2026-09-24 it announced a $155M Series E led by Francisco Partners with Thrive Capital and Khosla Ventures; Bloomberg reported a $1.75B valuation and $281M raised to date. Co-founder and CEO Jordan Feldman says an IPO is being weighed on a roughly four-year horizon.
Healthcare 📍 New York, NY
Current Valuation
$1.8B
as of 2026-09-24
UNICORN

QL Price

$1.8B
0% vs last round
QuantLogix's current estimate for Rightway, published 2026-09-25 — in line with the last disclosed round of $1.8B (2026-09-24).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round $1.8B 2026-09-24 weight 1
How this price has held up
No round has priced for Rightway since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-25 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Rightway →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Rightway, 2026-09-25 (f7959294955a17a9). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Rightway going public?
No. Rightway is private and has not filed to go public. There is no S-1 on file.
What is Rightway's valuation in 2026?
Rightway is valued at $1.8B as of 09/24/2026, set by its Series E ($155M, Sep 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Rightway filed an S-1?
No public S-1 is on file for Rightway.
Who are Rightway's investors?
Rightway's investors include Francisco Partners, Thrive Capital, Khosla Ventures, Tiger Global Management.
How much has Rightway raised?
Rightway has raised $281M in total across 3 disclosed rounds, most recently a Series E of $155M in Sep 2026.
Is Rightway publicly traded — can you buy Rightway stock?
No. Rightway is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Rightway on its Pre-IPO Access Desk.
How to actually get exposure to Rightway →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

CEO
Jordan Feldman
HQ
New York, NY
Total Raised
$281M
Growth
45 Fortune 500 clients; serves about 3 million people; profitable; Mayo Clinic slated to switch in January 2027 (Bloomberg, Sept 2026)
Last Round
Series E — $155M (Sep 2026) · Lead: Francisco Partners
IPO Status
private

Fundraising Status

Series E · $155M · this month
privateTotal raised $281M3 disclosed rounds

Series E Impact

Round Size
$155M
Primary financing announced
Post-Money Valuation
$1.8B
Company-announced mark
Valuation Step-Up
+59.1%
vs Series C at $1.1B
Round / Post-Money
8.9%
New capital ÷ post-money
Disclosed Funding
$281M
Cumulative disclosed rounds
Step-up compares disclosed post-money valuations. Round / post-money is a financing-size ratio, not an ownership or dilution estimate.

Growth & Valuation

Valuation across funding rounds
Valuation growth across funding rounds$1.1B$1.8BMar '21Sep '26
Capital raised per round
Capital raised per funding round$100MSeries C$109MSeries D (per SEC Form D)$155MSeries E
Charts built from publicly disclosed funding rounds and revenue estimates. Approximate, not real-time, not investment advice.

Funding History

RoundAmountDateLead InvestorPost-Money
Series E$155MSep 2026Francisco Partners$1.8B
Series D (per SEC Form D)$109MMar 2024——
Series C$100MMar 2021Khosla Ventures$1.1B

Talent Signal

Hiring data for Rightway has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.

Founders & Key People

Jordan Feldman

Investors

Francisco Partners · Thrive Capital · Khosla Ventures · Tiger Global Management

Products

  • RightwayRx pharmacy benefits (PBM)
  • SureSpend (Precision Pricing Guarantee, Zero-Markup Wrap)
  • Care navigation
  • Care Complete Weight Management

Competitors

CVS Caremark · Express Scripts (Cigna) · Optum Rx (UnitedHealth)
HealthcarePBMPharmacy BenefitsCare NavigationEmployer BenefitsUnicorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-09-24. Refreshed quarterly.